Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients

Lilly is committed to studying nearly 14,000 sepsis patients to meet its postmarketing obligations for its sepsis agent Xigris (drotrecogin alfa)

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet